Sigma-2 Receptor Modulation Therapy

Sigma-2 Receptor Modulation Therapy

Introduction

Sigma-2 Receptor Modulation Therapy

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-2 Receptor Modulation Therapy</th>
</tr>
<tr>
<td class="label">Study Phase</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>Alzheimer's disease (START study)</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>Dementia with Lewy Bodies</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>Dry age-related macular degeneration</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">CT1812</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">CT1812</td>
<td>Dementia with Lewy Bodies</td>
</tr>
<tr>
<td class="label">CT1964</td>
<td>Parkinson's disease</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Amyloid antibodies</td>
<td>Immun clearance</td>
</tr>
<tr>
<td class="label">BACE inhibitors</td>
<td>Amyloid reduction</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)-targeted</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">Symptomatic</td>
<td>Cholinergic</td>
</tr>
</table>

Sigma-2 receptor modulation therapy represents a novel therapeutic approach for neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). The sigma-2 receptor (also known as PPHLN1) is a unique transmembrane protein distinct from the sigma-1 receptor, and its modulation offers neuroprotective effects through multiple mechanisms including synaptic protection, ER stress modulation, calcium homeostasis, and [autophagy](/entities/autophagy) regulation["@phase2020"][@sigma2019].

Mechanism of Action

Synaptic Protection

The sigma-2 receptor is a key regulator of synaptic function and neuronal survival. Sigma-2 receptor antagonists such as CT1812 (selenex) prevent synaptic loss through several mechanisms:

• Dendritic spine integrity: Maintains the structural foundation of synaptic connections
• [Amyloid-beta](/proteins/amyloid-beta) toxicity protection: Shields synapses from toxic effects of amyloid-beta oligomers
• Neuronal connectivity preservation: Sustains communication between [neurons](/entities/neurons)
• Synaptic protein homeostasis: Regulates the balance of synaptic proteins

ER Stress Modulation

Sigma-2 receptors are localized to the endoplasmic reticulum (ER), where they play critical roles in cellular stress response[@sigma2019]:

• [Unfolded protein response](/entities/unfolded-protein-response) (UPR): Modulates ER stress pathways activated by protein misfolding
• Calcium handling: Regulates calcium release from ER stores, critical for neuronal signaling
• Pro-survival signaling: Activates pathways that promote cell survival under stress conditions

Calcium Homeostasis

The sigma-2 receptor modulates calcium signaling through[@phase2020][@calcium2020]:

• ER calcium channels: Regulates ryanodine and IP3 receptors
• Calcium-induced calcium release: Controls neuronal excitability
• Mitochondrial calcium: Interfaces with mitochondrial calcium handling
• Synaptic calcium: Modulates calcium dynamics at synaptic terminals

Autophagy Regulation

Sigma-2 modulation affects cellular clearance mechanisms[@sigma2019]:

• Lysosomal function: Receptor localizes to lysosomes, modulating autophagic flux
• Protein aggregate clearance: Enhances removal of misfolded protein aggregates
• Cellular quality control: Maintains neuronal health through improved clearance

Preclinical Evidence

Alzheimer's Disease Models

Preclinical studies have demonstrated sigma-2 receptor-mediated neuroprotection in AD models:

• Amyloid toxicity studies: Sigma-2 antagonists protect against amyloid-beta-induced synaptic damage
• Cognitive improvement: Animal models show improved memory and learning
• Synaptic marker preservation: Maintains postsynaptic density proteins
• Neuroinflammation reduction: Decreases pro-inflammatory markers

Parkinson's Disease Models

In PD models, sigma-2 modulation shows promise for[@sigma2021]:

• [Alpha-synuclein](/proteins/alpha-synuclein) protection: May protect against alpha-synuclein toxicity
• Mitochondrial function: Improves mitochondrial dynamics
• Dopaminergic neuron survival: Promotes survival of vulnerable dopamine neurons

Other Neurodegenerative Conditions

• Dementia with Lewy Bodies (DLB): Synaptic protection addresses key pathology
• Huntington's disease: Protein clearance mechanisms may help
• Frontotemporal dementia: ER stress modulation could be beneficial

Clinical Development

CT1812 (Selenex) - Lead Compound

CT1812 is a first-in-class small molecule sigma-2 receptor antagonist developed by Cognition Therapeutics (now part of Novartis)[@phase2020][@sigma2019]:

Key Properties:

• Oral bioavailability
• Brain penetrant
• Good safety profile
• Differentiated mechanism from amyloid antibodies

Clinical Trial Outcomes

Phase 1 Results:

• Safety and tolerability demonstrated in healthy volunteers
• Target engagement confirmed in cerebrospinal fluid
• Dose-proportional pharmacokinetics

• Evaluating cognitive outcomes (ADAS-Cog13, Cogstate)
• Measuring synaptic density biomarkers
• Assessing safety and tolerability

Pipeline Compounds

Safety Profile

Sigma-2 receptor modulators have demonstrated a favorable safety profile in clinical trials[@phase2020]:

• Generally well-tolerated: No significant safety concerns in Phase 1 studies
• No amyloid-related imaging abnormalities (ARIA): Unlike amyloid antibodies
• Peripheral effects: Minimal peripheral side effects
• Drug-drug interactions: Favorable interaction profile

Comparison with Other Approaches

Sigma-2 modulation offers advantages over existing AD therapeutics:

Cross-Links

Related Mechanisms

• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [ER Stress Pathway](/mechanisms/er-stress-pathway)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy-lysosomal-pathway)
• [Calcium Signaling in Neurons](/mechanisms/calcium-signaling-neurons)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)

Related Cell Types

• [Sigma-2 Receptor Neurons](/cell-types/sigma-2-receptor-neurons)
• [Hippocampal Neurons](/cell-types/hippocampal-neurons)
• [Cortical Neurons](/cell-types/cortical-neurons)

Related Treatments

• [Amyloid Immunotherapy](/therapeutics/amyloid-immunotherapy-alzheuers)
• [BACE1 Inhibitors](/therapeutics/bace1-inhibitors-neurodegeneration)

Future Directions

• Combination therapy: Potential combination with amyloid-targeting agents
• Biomarker development: Validation of synaptic density biomarkers
• Broader indications: Exploration in additional neurodegenerative conditions
• Patient stratification: Identification of optimal responder populations

See Also

• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [ER Stress Pathway](/mechanisms/er-stress-pathway)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy-lysosomal-pathway)
• [Calcium Signaling in Neurons](/mechanisms/calcium-signaling-neurons)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
• [Amyloid Immunotherapy](/therapeutics/amyloid-immunotherapy-alzheuers)
• [BACE1 Inhibitors](/therapeutics/bace1-inhibitors-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BACE1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;